NEW YORK (GenomeWeb) – CRISPR Therapeutics announced today that it has raised an additional $38 million as part of a Series B Financing round.

The company said the funding round raised almost $140 million overall, with the first part of the financing being led by Vertex Pharmaceuticals and Bayer Global Investments, and the second, oversubscribed closing including new institutional investors and specialized healthcare funds such as Franklin Templeton Investments, New Leaf Venture Partners, and funds advised by Clough Capital Partners and Wellington Capital Management.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Magdalena Skipper, the incoming editor-in-chief of Nature, speaks with NPR's Weekend Edition Sunday.

Genetic genealogy has led to an arrest in another cold case, dating back to 1987.

In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.

Wired reports that 23andMe is trying to bolster its outside collaborations.